Response to "Pharmacogenetics of Voriconazole: CYP2C19 but Also CYP3A4 Need to Be Genotyped" - The Role of CYP3A4 and CYP3A5 Polymorphisms in Clinical Pharmacokinetics of Voriconazole

被引：5

作者：

Walsh, T. J. ^{[1
,2
,3
]}

Moriyama, B. ^{[4
]}

Penzak, S. R. ^{[5
]}

Klein, T. E. ^{[6
]}

Caudle, K. E. ^{[7
]}

机构：

[1] Cornell Univ, Weill Cornell Med Ctr, Transplantat Oncol Infect Dis Program, Dept Med, New York, NY 10065 USA

[2] Cornell Univ, Weill Cornell Med Ctr, Transplantat Oncol Infect Dis Program, Dept Pediat, New York, NY 10065 USA

[3] Cornell Univ, Weill Cornell Med Ctr, Transplantat Oncol Infect Dis Program, Dept Microbiol & Infect Dis, New York, NY 10065 USA

[4] NIH, Ctr Clin, Dept Pharm, Bethesda, MD 20892 USA

[5] Univ North Texas Syst, Coll Pharm, Dept Pharmacotherapy, Ft Worth, TX USA

[6] Stanford Univ, Dept Biomed Data Sci, Stanford, CA 94305 USA

[7] St Jude Childrens Res Hosp, Dept Pharmaceut Sci, 332 N Lauderdale St, Memphis, TN 38105 USA

来源：

CLINICAL PHARMACOLOGY & THERAPEUTICS | 2017年 / 102卷 / 02期

关键词：

ANTIFUNGAL AGENT;

D O I：

10.1002/cpt.681

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

引用

页码：190 / 190

页数：1

共 8 条

[1]

Barbarino J.M., PHARMACOGEN IN PRESS

[2] Pharmacogenetics of Voriconazole: CYP2C19 but Also CYP3A4 Need to Be Genotyped [J].

Gautier-Veyret, E. ;

Fonrose, X. ;

Stanke-Labesque, F. .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 2017, 102 (02) :189-189

[3] A genetic score combining CYP450 2C19 and 3A4 genotypes to predict voriconazole plasma exposure? [J].

Gautier-Veyret, Elodie ;

Fonrose, Xavier ;

Stanke-Labesque, Francoise .

INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2016, 48 (02) :221-222

[4] Effects of CYP3A4 polymorphisms on the plasma concentration of voriconazole [J].

He, H. -R. ;

Sun, J. -Y. ;

Ren, X. -D. ;

Wang, T. -T. ;

Zhai, Y. -J. ;

Chen, S. -Y. ;

Dong, Y. -L. ;

Lu, J. .

EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 2015, 34 (04) :811-819

[5]

Mikus G, 2011, PHARMACOGENOMICS, V12, P861, DOI [10.2217/PGS.11.18, 10.2217/pgs.11.18]

[6] Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP2C19 and Voriconazole Therapy [J].

Moriyama, B. ;

Obeng, A. Owusu ;

Barbarino, J. ;

Penzak, S. R. ;

Henning, S. A. ;

Scott, S. A. ;

Agundez, J. A. G. ;

Wingard, J. R. ;

McLeod, H. L. ;

Klein, T. E. ;

Cross, S. J. ;

Caudle, K. E. ;

Walsh, T. J. .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 2017, 102 (01) :45-51

[7] Roles of CYP3A4 and CYP2C19 in methyl hydroxylated and N-oxidized metabolite formation from voriconazole, a new anti-fungal agent, in human liver microsomes [J].

Murayama, Norie ;

Imai, Naoko ;

Nakane, Takahisa ;

Shimizu, Makiko ;

Yamazaki, Hiroshi .

BIOCHEMICAL PHARMACOLOGY, 2007, 73 (12) :2020-2026

[8] Inflammation Is Associated with Voriconazole Trough Concentrations [J].

van Wanrooy, Marjolijn J. P. ;

Span, Lambert F. R. ;

Rodgers, Michael G. G. ;

van den Heuvel, Edwin R. ;

Uges, Donald R. A. ;

van der Werf, Tjip S. ;

Kosterink, Jos G. W. ;

Alffenaar, Jan-Willem C. .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2014, 58 (12) :7098-7101

← 1 →